Coagulation factor II, thrombin

Overview

Coagulation factor II, thrombin is a central serine protease in the coagulation cascade and the active enzymatic form of prothrombin (coagulation factor II). It plays a pivotal role in hemostasis by converting fibrinogen to fibrin, promoting clot formation, and amplifying coagulation through activation of other clotting factors and platelets. Because of these functions, thrombin is both a key physiological mediator of blood clotting and an important therapeutic target in thrombosis and anticoagulation research.

Beyond its classical role in coagulation, thrombin is also implicated in inflammatory and fibrotic signaling. Recent biomedical studies have linked thrombin activity to disease processes such as sepsis, pulmonary fibrosis, and broader coagulation abnormalities. Its signaling effects can involve pathways such as PAR-1-mediated responses and interactions with growth factors including TGF-β1 and VEGF, making thrombin relevant not only to thrombosis but also to inflammation, tissue remodeling, and vascular pathology.

Recent Publications Focus

Below is a summary of the newest research publications targeting Coagulation factor II, thrombin (sorted by publication date).

Thrombin has been investigated as both a primary therapeutic target in anticoagulation and a secondary target in pathological inflammatory and fibrotic responses. Direct oral anticoagulants (DOACs) targeting thrombin represent the established standard for preventing thrombotic diseases including myocardial infarction, stroke, and venous thromboembolism [PMID 41485707]; however, clinical use remains limited by persistent and significant bleeding risks [PMID 41485707]. Recent investigations have expanded thrombin's therapeutic relevance to tissue remodeling and inflammatory disease, positioning thrombin inhibition as a multifaceted therapeutic strategy.

Thrombin inhibition has been explored in pulmonary fibrosis and ischemic stroke. The serine protease inhibitor hirudin was investigated for its ability to alleviate paraquat-induced pulmonary fibrosis through thrombin targeting and the PAR-1-mediated transforming growth factor-β1 (TGF-β1) pathway [PMID 41085213]. In ischemic stroke, network pharmacology approaches identified thrombin (F2) as a core target affected by Curcumae Rhizoma compounds [PMID 42301551]. Molecular docking revealed that Curcumae Rhizoma components, particularly alexandrin and hederagenin, exhibited potent binding affinities for thrombin [PMID 42301551]. In vivo studies using a mouse model of middle cerebral artery occlusion demonstrated that Curcumae Rhizoma extract reduced infarct volume and improved motor recovery; network analysis predicted thrombin interaction as a secondary mechanism alongside the primary anti-inflammatory effects mediated by Prostaglandin-endoperoxide synthase 2 inhibition [PMID 42301551].

Thrombin generation has been identified as a quantifiable biomarker for prothrombotic states linked to metabolic dysfunction and obesity. Research examining associations between abdominal adipose tissue and venous thromboembolism risk in middle-aged adults identified correlations between visceral and subcutaneous adiposity with altered thrombin generation parameters, including endogenous thrombin potential and peak thrombin levels [PMID 42131917]. These findings indicate that increased abdominal adiposity is associated with measurable prothrombotic changes in thrombin-dependent hemostatic markers.

Dysregulation of thrombin is implicated in allergic disease through modulation of coagulation and complement cascades. Multi-omics integration including metabolomics, network pharmacology, and proteomics identified differential metabolites associated with altered expression of coagulation cascade proteins, including thrombin (F2), in bovine serum albumin-induced allergic responses [PMID 41385805]. These mechanistic insights suggest thrombin's pathophysiological role extends beyond hemostasis to include immune regulation and allergic disease pathogenesis [PMID 41385805].